Rothermundt C, et al. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Swiss Med Wkly. 2018;148:w14640. DOI: https://doi.org/10.4414/smw.2018.14640
Dr G Silke’s second affiliation has been added: a Klinik für Medizinische Onkologie und Hämatologie, Departement Innere Medizin, Kantonsspital St. Gallen, Switzerland
All references to “non-seminoma tumour(s)” are now “non-seminoma(s)”.
The interquartile ranges for tumour size are reported separately for the two tumour types: 2.5‒5.0 and 2.3‒4.5 cm for seminomas and non-seminomas, respectively. The number of patients who did not receive therapy that conformed with guidelines was 11 (not 5).
Results: Tumour markers and stage of disease
In stage III seminoma, 72.7% of patients had marker-positive disease (not 66.7%).
Results: Table 4
For the patients with stage III seminoma, the percentages reported for each treatment regimen are the proportion of the prognosis group (not the treatment type).
Any tumour marker was elevated in non-seminoma stage I in 64.9% (not 64.5%) of patients.